Panel: Biopharma's Response to Policy Whiplash

Session details:

The convergence of FDA leadership transitions, intensified pricing pressures, and persistent tariff threats has created an unprecedented policy environment for pharmaceutical companies. How industry leaders navigate this regulatory maze while maintaining innovation pipelines and investor confidence will define competitive advantage in the coming years. This panel will examine the strategic adaptations companies have made and the political realities they must master.